Evidence map›Paper›PMID 37846575›Full record

ArticleEndocrine, metabolic & immune disorders drug targets2024

Current Views About the Link between SARS-CoV-2 and the Liver: Friends or Foe?

Roberto Lovero, Ioannis Alexandros Charitos, Skender Topi, Francesca Castellaneta, Angela Pia Cazzolla, Marica Colella

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, metabolic & immune disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Roberto LoveroClinical Pathology Unit, AOU Policlinico Consorziale di Bari - Ospedale Giovanni XXIII, Bari 70124, Italy.ORCID 0000-0001-7580-5733
Ioannis Alexandros CharitosDepartment of Clinical Disciplines, University of Elbasan, Elbasan, 3001, Albania.ORCID 0000-0003-3527-7483
Skender TopiDepartment of Clinical Disciplines, University of Elbasan, Elbasan, 3001, Albania.ORCID 0000-0002-6661-8116
Francesca CastellanetaClinical Pathology Unit, AOU Policlinico Consorziale di Bari - Ospedale Giovanni XXIII, Bari 70124, Italy.ORCID 0000-0003-4555-5520
Angela Pia CazzollaDepartment of Clinical and Experimental Medicine, Università degli Studi di Foggia, Foggia, 71122, Italy.ORCID 0000-0003-0842-7351
Marica ColellaInterdisciplinary Department of Medicine, Section of Microbiology and Virology, Università degli Studi di Bari, 70124, Bari, Italy.ORCID 0000-0003-0806-4327

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of the novel coronavirus and the pandemic resulting from its spread have led to significant negative impacts on health, economy, relationships, and others. Particularly in the field of hospital care, the need for a greater number of patients has led to a breakdown of the system. Gastrointestinal manifestations are common in SARS-COV 2 patients, while 10% of those who are sick exhibit symptoms only from gastrointestinal without any manifestation on the part of the respiratory tract. The main manifestations are nausea, vomiting, diarrhoea, and anorexia. It is also interesting to note that biochemical liver disorder is a frequent finding and is associated with a worse prognosis and higher probability admission to intensive care. It was also observed that RNA from the virus was found in the stool several days after the tests came back negative pulmonary secretions, while rectal swab virus detection methods were used with a lower but comparable sensitivity to that of nasal swabs. Gastrointestinal symptoms in SARS-COV 2 infection are common and their search should be part of the initial diagnosis approach and have a connection with the gut microbiota dysbiosis and this can lead to an alteration of the gut/liver axis.

Indexed as

COVID-19SARS-CoV-2FriendsGastrointestinal TractHumansLiverclinical microbiologyCOVID-19gut/liver axis.gut microbiotaHepatologyliver biochemistrypandemicsSARS-CoV 2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.